Skip to main content

Advertisement

Log in

Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Osteoporosis is characterized by skeletal fragility and microarchitectural deterioration. The side effects of drugs to treat osteoporosis will negatively affect the health of patients. This study aimed to investigate the therapeutic effects of icariin combined with adipose-derived stem cells on osteoporosis in a postmenopausal osteoporosis model after ovariectomy in rats. After ovariectomy the rats were treated with icariin combined with adipose-derived stem cell transplantation. The levels of alkaline phosphatase, tartrate-resistant acid phosphatase, osteoprotegerin, and bone γ-carboxyglutamate protein in serum were determined by ELISA. The bone mineral density was measured by dual-energy X-ray absorptiometry. The mechanical properties were determined by a three-point bending test. The kidney functions were evaluated by an automatic analyzer and a diagnostic kit. Icariin combined with stem cells significantly reduced body weight gain caused by ovariectomy, significantly decreased alkaline phosphatase, tartrate-resistant acid phosphatase, and bone γ-carboxyglutamate protein content in serum, significantly increased osteoprotegerin content, significantly elevated bone mineral density of the lumbar spine, left femur, and right femur, and enhanced bone biomechanical properties of the femur, including maximum bending load, bending rigidity, and fracture energy, in osteoporotic rats. In addition, icariin combined with stem cells substantially decreased the damage to the liver and kidney in osteoporotic rats. Icariin combined with stem cells can not only ameliorate reduction of bone mass and disruption of the microarchitectural structure of bone tissue caused by osteoporosis in a rat model but can also have a beneficial effect on organ functions, such as those of the liver and kidney.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lindsay R (1993) Pathogenesis of postmenopausal osteoporosis. Baillieres Clin Rheumatol 7:499–513

    Article  CAS  Google Scholar 

  2. Edwards BJ, Brooks ER, Langman CB (2004) Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach. Gend Med 1:70–85

    Article  Google Scholar 

  3. Meeta Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations. J Midlife Health 4:107–126

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381

    Article  CAS  Google Scholar 

  5. Leung PC, Siu WS (2013) Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 3:82–87

    Article  Google Scholar 

  6. Hinton PS, Nigh P, Thyfault J (2015) Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 79:203–212

    Article  Google Scholar 

  7. Evans RK, Negus CH, Centi AJ, Spiering BA, Kraemer WJ, Nindl BC (2012) Peripheral QCT sector analysis reveals early exercise induced increases in tibial bone mineral density. J Musculoskelet Neuronal Interact 12:155–164

    CAS  PubMed  Google Scholar 

  8. Bauer DC (2013) Calcium supplements and fracture prevention. N Engl J Med 369:1537–1543

    Article  CAS  Google Scholar 

  9. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683

    Article  CAS  Google Scholar 

  10. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta analysis. J Clin Endocrinol Metab 97:1871–1880

    Article  CAS  Google Scholar 

  11. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738

    Article  CAS  Google Scholar 

  12. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723

    Article  Google Scholar 

  13. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  Google Scholar 

  14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  Google Scholar 

  15. Qin L, Zhang G, Hung WY, Shi Y, Leung K, Yeung HY, Leung P (2005) Phytoestrogen rich herb formula “XLGB” prevent OVX-induced deterioration of musculoskeletal tissues. J Bone Miner Metab 23:55–61

    Article  Google Scholar 

  16. Zhang Y, Lai WP, Wong MS (2006) Effects of Fracutus Ligustri Lucidi extract on bone turn over and calcium balance in ovariectomized rats. Biot Pharm Bull 29:291–296

    Article  Google Scholar 

  17. Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD (2014) Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. Menopause 21:1007–1016

    Article  Google Scholar 

  18. Mao XY, Bian Q, Shen ZY (2012) Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Zhong Xi Yi Jie He Xue Bao 10:1272–1278

    Article  CAS  Google Scholar 

  19. Levis S, Theodore GJ (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Manag Care Pharm 18:S1–15

    Article  Google Scholar 

  20. Black DM (2016) Postmenopausal osteoporosis. N Engl J Med 374:254–262

    Article  CAS  Google Scholar 

  21. Kapoor S (2013) Icariin and its emerging role in the treatment osteoporosis. Chin Med J (Engl) 126:400

    Google Scholar 

  22. Liu M, Zhong C, He RX, Chen LF (2012) Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl) 125:1784–1789

    CAS  Google Scholar 

  23. Zhang G, Qin L, Shi Y (2007) Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double- blind and placebo-controlled trial. J Bone Miner Res 22:1072–1079

    Article  CAS  Google Scholar 

  24. Caplan AI (2015) Adult mesenchymal stem cells and women’s health. Menopause 22:131–135

    Article  Google Scholar 

  25. Kwak EJ, Lee YS, Choi EM (2012) Effect of magnolol on the function of osteoblastic MC3T3-E1 cells. Mediat Inflamm 2012:829650

    Article  Google Scholar 

  26. Eastell R, Reid DM, Vukicevic S, Ensrud KE, LaCroix AZ, Thompson JR, Thompson DD, Cummings SR (2012) Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 50:1135–1140

    Article  CAS  Google Scholar 

  27. Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, Wong MS (2010) Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 159:939–949

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dongbo Wang.

Ethics declarations

Conflict of interest

The authors declares no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, D., Ju, C., Liu, Y. et al. Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats. J Bone Miner Metab 36, 180–188 (2018). https://doi.org/10.1007/s00774-017-0831-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-017-0831-x

Keywords

Navigation